What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer

GRACEcast by Howard (Jack) West, MD

"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).